No indication for thrombophilia screening in patients with idiopathic venous thromboembolism and their relatives;Geen indicatie voor trombofilieonderzoek bij patiënten met idiopathische veneuze trombo-embolie en hun familieleden

Nederlands Tijdschrift voor Geneeskunde

Volumn 145, Issue 22, 2001, Pages 1047-1051

  Middeldorp, S ^a   Prins, M H ^a   Buller H R ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN; BLOOD CLOTTING FACTOR 5 LEIDEN; BLOOD CLOTTING FACTOR 8; LUPUS ANTICOAGULANT; PHOSPHOLIPID ANTIBODY; PROTEIN C; PROTEIN S; PROTHROMBIN;

ARTICLE; DIAGNOSTIC APPROACH ROUTE; GENE MUTATION; HEALTH CARE POLICY; HIGH RISK PATIENT; HUMAN; HYPERHOMOCYSTEINEMIA; RECURRENT DISEASE; RELATIVE; RISK FACTOR; SCREENING; SYMPTOM; THROMBOEMBOLISM; THROMBOPHILIA; VEIN THROMBOSIS;

DIAGNOSIS, DIFFERENTIAL; HUMANS; MASS SCREENING; RECURRENCE; THROMBOEMBOLISM; THROMBOPHILIA; VENOUS THROMBOSIS;

EID: 0035795956     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Inherited antithrombin deficiency causing thrombophilia
2. Deficiencies of coagulation-inhibiting and fibrinolytic proteins in outpatients with deep-vein thrombosis
3. Antiphospholipid antibodies and venous thromboembolism
4. Deep venous thrombosis and lupus anticoagulant. A case-control study
5. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: Prediction of a cofactor to activated protein C
6. Mutation in blood coagulation factor V associated with resistance to activated protein C
7. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis
8. Prevalence of moderate hyperhomocysteinemia in patients with early-onset venous and arterial occlusive disease
9. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis
10. CBO-richtlijn 'Diepveneuze trombose en longembolie': Herziening van eerdere richtlijnen
11. How to decide on the optimal duration of anticoagulant therapy in carriers of the factor V Leiden mutation
12. Optimal duration of oral anticoagulant therapy: A randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis
13. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism
14. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism
15. Three-months compared with one-year of oral anticoagulant treatment after a first idiopathic deep vein thrombosis: The Warfarin Optimal Duration Italian Trial (WODIT)
16. Factor V Leiden and risks of recurrent idiopathic venous thromboembolism
17. The risk of recurrent venous thromboembolism in patients with an Arg506→Gln mutation in the gene for factor V (factor V Leiden)
18. Probability of recurrence of thrombosis in patients with and without factor V Leiden
19. The risk of recurrent venous thromboembolism in patients with and without factor V Leiden
20. Risk of recurrent venous thromboembolism in patients with the factor V Leiden (FVR506Q) mutation: Effect of warfarin and prediction by precipitating factors
21. The risk of recurrent venous thromboembolism in carriers and non-carriers of the G1691A allele in the coagulation factor V gene and the G202210A allele in the prothrombin gene
22. Clinical manifestations and management of inherited thrombophilia: Retrospective analysis and follow-up after diagnosis of 238 patients with congenital deficiency of antithrombin III, protein C, protein S
23. Recurrence of venous thromboembolism in patients with familial thrombophilia
24. The risk of early recurrent venous thromboembolism after oral anticoagulant therapy in patients with the G20210A transition in the prothrombin gene
25. Hyperhomocysteinemia is a risk factor of recurrent venous thromboembolism
26. High plasma levels of factor VIII and the risk of recurrent venous thromboembolism
27. Bleeding complications of oral anticoagulant treatment: An inception-cohort, prospective collaborative study (ISCOAT)
28. Assessment of a bleeding risk index in two cohorts of patients treated with oral anticoagulants
29. Extended anticoagulation for prevention of recurrent venous thromboembolism in carriers of fac tor V Leiden - Cost-effectiveness analysis
30. Duration of oral anticoagulant treatment in patients with venous thromboembolism and a deficiency of antithrombin, protein C or protein S - A decision analysis
31. The incidence of venous thromboembolism in family members of patients with factor V Leiden mutation and venous thrombosis
32. Incidence of venous thromboembolism in families with inherited thrombophilia